Asset profile
Capivasertib
Small molecule
Evidence outlook
Approved: HR+/HER2- Metastatic Breast Cancer (label: HR+/HER2- locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN...)
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
62 competitors in this universe: 2 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Capivasertib: this drug | Approved | Small molecule | AKT (inhibitor) | ||
| Afuresertib | Phase 3 | Small molecule | AKT (inhibitor) | ||
| NTQ1062 | Phase 3 | Small molecule | AKT (inhibitor) | ||
| Abemaciclib (Verzenio) | Approved | Small molecule | CDK4 and CDK6 | ||
| Alpelisib (BYL719) | Approved | Small molecule | PI3K-alpha | ||
| Anastrozole | Approved | Small molecule | Aromatase | ||
| Capecitabine | Approved | Small molecule | Fluoropyrimidine (antimetabolite) | ||
| Datopotamab Deruxtecan | Approved | Antibody–drug conjugate | TROP2 | ||
| Denosumab | Approved | Monoclonal antibody | RANKL | ||
| Docetaxel | Approved | Small molecule | Microtubules (tubulin) | ||
| Elacestrant | Approved | Small molecule | Estrogen receptor | ||
| Eribulin Mesylate | Approved | Small molecule | Tubulin / microtubules | ||
| Everolimus | Approved | Small molecule | mTOR kinase, mTOR (mTORC1) (inhibitor) | ||
| Exemestane | Approved | Small molecule | Aromatase | ||
| Fulvestrant (Faslodex) | Approved | Small molecule | Estrogen receptor | ||
| Gedatolisib | Approved | Small molecule | PI3K (class I isoforms) and mTORC1/mTORC2 |
…and 47 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(21 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (5)
October 2026 (1)
What to watch
November 2026 (1)
What to watch
December 2026 (3)
What to watch
What to watch
What to watch
2027 (7)
January 2027 (1)
What to watch
April 2027 (1)
What to watch
May 2027 (1)
What to watch
June 2027 (1)
What to watch
November 2027 (1)
What to watch
2028 (4)
February 2028 (1)
What to watch
March 2028 (1)
What to watch
June 2028 (1)
What to watch
October 2028 (1)
What to watch
2030 (1)
March 2030 (1)
What to watch
2031 (2)
February 2031 (1)
What to watch
October 2031 (1)
What to watch
2032 (1)
March 2032 (1)
What to watch
2034 (1)
October 2034 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.